Introduction
With stem cells' ability to initiate regenerative processes in the brain, stem cell transplantation may be a viable method for ameliorating neurological diseases and disorders. Prior research has demonstrated that cell-based therapies heal brain tissue by cell replacement and secretion of neurotrophic factors in various diseases such as ischemic stroke, traumatic brain injury, and Parkinson's disease (PD). Given the prevalence and severity of these maladies and the promising evidence regarding stem cell transplantation in preclinical animal models, further research and improvements to stem cell therapies are warranted. Moreover, alternative strategies to increase the limited available treatments for these and other brain diseases are welcomed. In this special issue, we explore new methods and knowledge to improve stem cell transplantation in diseases and conditions such as stroke, PD, and depression. Advancing the conventional idea regarding cell replacement in stem cell therapy, stem cells may also transfer healthy mitochondria to diseased ischemic neurons in stroke and improve the therapeutic time window of tissue plasminogen activator (tPA) in a conjunctive therapy for stroke, and human Wharton's Jelly-derived mesenchymal stromal cells (hWJ-MSCs) may rely mainly on trophic factor secretion to induce neuroprotective effects. In addition, trophic factors such as neurotrophin-4/5 (NT-4/5) and glial cell line-derived neurotrophic factor (GDNF) may enhance stem cell survival and differentiation to dopaminergic neurons for PD treatment, while encapsulating mesenchymal stem cells and GDNF-secreting cells may increase graft survival rates and their ability to promote neurogenesis and neurotrophic factor secretion in therapies for depression and PD. Of note, transfecting stem cells with a contrast agent such as a superparamagnetic iron oxide (SPIO) for tracking with magnetic resonance imaging (MRI) after transplantation may render these transplanted cells more vulnerable to toxicity in ischemic and hypoxic conditions. Moreover, other methods such as transient microglia depletion may protect against cosmic radiation-induced cognitive impairments, and focusing on the collaborative efforts between oligodendrocytes and the neurovascular unit cells to repair damaged white matter may improve therapies for white matter injury. The following ten reviews encompass pertinent investigations regarding regenerative therapies for several central nervous system (CNS) diseases and disorders. Ultimately, this editorial highlights innovative strategies and the current knowledge regarding the utility of stem cells and other cells such as microglia and oligodendrocytes in CNS repair, in the hopes of spawning novel therapies to bolster and increase the insufficient number of effective treatments for the aforementioned diseases and conditions.
Chapter 1 -Mitochondrial Targeting as a Novel Therapy for Stroke
Dr. Eleonora Napoli from the University of California, Davis, California, USA, and her collaborators from the University of South Florida (Florida, USA) show that mitochondrial dysfunction is central in ischemic injury, and recent findings of mitochondria transfer from stem cells to damaged cells pave the way for a novel promising strategy for stroke. Stroke is the second leading cause and death worldwide behind heart diseases. Interestingly, the transfer of healthy mitochondria in injured cells by promoting survival, reducing oxidative stress, and restoring bioenergetics proliferation could be an effective strategy for the treatment of stroke. 
Chapter 2 -Healthy Mitochondria for Stroke Cells

Chapter 7 -Human Wharton's Jelly-derived Mesenchymal Stromal Cell Transplant Reduces Ischemic Brain Injury through Glial Cell Line-Derived Neurotrophic Factor
Dr. Yun Wang et al. from the National Health Research Institutes of Miaoli (Taiwan) demonstrate that hWJ-MSC transplantation significantly decreased brain infarction and microglia activation in the penumbra leading to a significant reduction of neurological deficits. Interestingly, the incorporation of most of the grafted hWJ-MSCs into IBA1 (+) cells and the increase of GDNF expression in the host brain suggest that the protective effect of hWJ-MSCs may not be led to the survival of the grafted cells, but it may be due to the secretion of trophic factors. 
Conclusion
Stem cell therapies and relevant cell-based regenerative medicine approaches hold promise for improving the outcomes of CNS diseases and disorders and may be enhanced by additional knowledge, modification, and novel applications of stem cells, such as stem cell-mediated mitochondrial transfer and stem cell encapsulation. Furthermore, alternative approaches such as transient microglia depletion and emphasizing oligodendrocyte-associated white matter recovery also appear to be effective potential strategies for CNS rehabilitation. Thus, future studies that improve our understanding of these methods will be necessary to enhance regenerative and neuroprotective therapies for stroke, PD, depression, cosmic radiation-induced cognitive impairment, white matter injury, and other related diseases and conditions in the clinic.
